Steatohepatitis/Metabolic Liver Disease News

Objectively measured physical activity was associated with lower all-cause mortality in patients with non-alcoholic fatty liver disease, according to research published in Clinical Gastroenterology and Hepatology.

Data from the UK BioBank demonstrated patients with obesity and fatty liver had an increased risk for symptomatic COVID-19 infection, according to a release from Perspectum.

The FDA issued a complete response letter for the new drug application for obeticholic acid for treatment of fibrosis due to nonalcoholic steatohepatitis, according to a press release from Intercept Pharmaceutical Inc.

Inventiva announced lanifibranor met primary and secondary endpoints in a phase 2b study for treatment of nonalcoholic steatohepatitis, according to speaker at an Inventiva web conference.

Among U.S. adults with type 2 diabetes attending primary care and endocrinology clinics, less than 40% of those found to have liver fibrosis had elevated aspartate aminotransferase and alanine aminotransferase, according to study data.

Over one-third of patients admitted to the hospital with SARS-CoV-2 infection had abnormal liver function that correlated with longer hospital stay than patients with normal liver function, according to a study published in Clinical Gastroenterology and Hepatology.

Women have a lower risk for developing nonalcoholic fatty liver disease than men, but they have a higher risk for advanced fibrosis once it is established, according to study results.

Nonalcoholic steatohepatitis is a severe form of fatty liver disease that affects 3% to 5% of the population in the United States and currently no approved drugs are available for treatment, according to a press release from Durect Corporation.

Endoscopically placed intragastric balloons appeared to be safe and effective for the management of NASH, according to research published in Clinical Gastroenterology and Hepatology.

In this exclusive video, Nancy S. Reau, MD, section chief of hepatology and associate director of organ transplantation at Rush University Medical Center, discusses some important aspects of treating liver diseases during the COVID-19 pandemic.